phrykt

InMed Pharmaceuticals Inc. (MTRI): who owns it and who trades it

As of Nov 16, 2026, MTRI insiders reported 50 purchases worth $1.4M in the last 12 months. The largest buyer was Daniel Schneeberger (10% owner), with $840K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling InMed Pharmaceuticals

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, MTRI insiders reported $1.4M of open-market purchases and $0 of sales.

Purchases, 12 months
$1.4M
50 trades, 4 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 5, 2026
Filed Nov 9, 2026

Purchases and sales by month

$895K$895KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 5, 2026ADAR1 Capital Management, LLC +110% ownerPurchase2,640$13.10$34.6KForm 4
Oct 23, 2026ADAR1 Capital Management, LLC +110% ownerPurchase4$1.32$5Form 4
Oct 19, 2026ADAR1 Capital Management, LLC +110% ownerPurchase1,086$1.32$1.4KForm 4
Oct 16, 2026ADAR1 Capital Management, LLC +110% ownerPurchase1$1.32$1Form 4
Oct 15, 2026ADAR1 Capital Management, LLC +110% ownerPurchase984$1.32$1.3KForm 4
Oct 14, 2026ADAR1 Capital Management, LLC +110% ownerPurchase8,021$1.33$10.7KForm 4
Oct 13, 2026ADAR1 Capital Management, LLC +110% ownerPurchase564$1.33$750Form 4
Oct 8, 2026ADAR1 Capital Management, LLC +110% ownerPurchase2,256$1.33$3KForm 4
Oct 7, 2026ADAR1 Capital Management, LLC +110% ownerPurchase3,046$1.33$4.1KForm 4
Oct 6, 2026ADAR1 Capital Management, LLC +110% ownerPurchase5,601$1.33$7.4KForm 4
Oct 5, 2026ADAR1 Capital Management, LLC +110% ownerPurchase18,182$1.33$24.2KForm 4
Oct 2, 2026ADAR1 Capital Management, LLC +110% ownerPurchase8,307$1.33$11KForm 4
Oct 1, 2026ADAR1 Capital Management, LLC +110% ownerPurchase16,431$1.33$21.8KForm 4
Sep 16, 2026Daniel Schneeberger +110% ownerPurchase8,340$1.29$10.8KForm 4
Sep 15, 2026Daniel Schneeberger +110% ownerPurchase54,256$1.30$70.5KForm 4
Sep 14, 2026Daniel Schneeberger +110% ownerPurchase28,505$1.29$36.8KForm 4
Jul 16, 2026Vivo Opportunity Cayman Fund, L.P. +310% ownerPurchase2$1.55$3Form 4
Jul 16, 2026Vivo Opportunity Cayman Fund, L.P. +310% ownerPurchase19$1.55$29Form 4
Jul 15, 2026ADAR1 Capital Management, LLC +110% ownerPurchase1,000$1.56$1.6KForm 4
Jul 15, 2026Vivo Opportunity Cayman Fund, L.P. +310% ownerPurchase1,389$1.55$2.2KForm 4
Jul 15, 2026Vivo Opportunity Cayman Fund, L.P. +310% ownerPurchase13,761$1.55$21.3KForm 4
Jul 14, 2026Vivo Opportunity Cayman Fund, L.P. +310% ownerPurchase493$1.55$764Form 4
Jul 14, 2026Vivo Opportunity Cayman Fund, L.P. +310% ownerPurchase4,882$1.55$7.6KForm 4
Jul 2, 2026Vivo Opportunity, LLC +310% ownerPurchase147$1.55$228Form 4
Jul 2, 2026Vivo Opportunity, LLC +310% ownerPurchase1,460$1.55$2.3KForm 4
Jul 1, 2026Vivo Opportunity, LLC +310% ownerPurchase398$1.55$617Form 4
Jul 1, 2026Vivo Opportunity, LLC +310% ownerPurchase3,946$1.55$6.1KForm 4
Jun 30, 2026Vivo Opportunity, LLC +310% ownerPurchase545$1.54$839Form 4
Jun 30, 2026Vivo Opportunity, LLC +310% ownerPurchase55$1.54$85Form 4
Jun 8, 2026Vivo Opportunity, LLC +310% ownerPurchase2,982$1.52$4.5KForm 4
Jun 8, 2026Vivo Opportunity, LLC +310% ownerPurchase29,518$1.52$44.9KForm 4
Jun 5, 2026Vivo Opportunity, LLC +310% ownerPurchase49,966$1.57$78.4KForm 4
Jun 5, 2026Vivo Opportunity, LLC +310% ownerPurchase5,045$1.57$7.9KForm 4
Jun 4, 2026Vivo Opportunity, LLC +310% ownerPurchase6,125$1.57$9.6KForm 4
Jun 4, 2026Vivo Opportunity, LLC +310% ownerPurchase618$1.57$970Form 4
Jun 3, 2026Vivo Opportunity, LLC +310% ownerPurchase7,069$1.55$11KForm 4
Jun 3, 2026Vivo Opportunity, LLC +310% ownerPurchase714$1.55$1.1KForm 4
Jun 2, 2026Vivo Opportunity, LLC +310% ownerPurchase20,753$1.52$31.5KForm 4
Jun 2, 2026Vivo Opportunity, LLC +310% ownerPurchase2,095$1.52$3.2KForm 4
Jun 1, 2026Vivo Opportunity, LLC +310% ownerPurchase14,838$1.55$23KForm 4
Jun 1, 2026Vivo Opportunity, LLC +310% ownerPurchase1,498$1.55$2.3KForm 4
May 29, 2026Vivo Opportunity, LLC +310% ownerPurchase16,164$1.57$25.4KForm 4
May 29, 2026Vivo Opportunity, LLC +310% ownerPurchase1,632$1.57$2.6KForm 4
May 21, 2026Vivo Opportunity, LLC +310% ownerPurchase30,882$1.69$52.2KForm 4
May 21, 2026Vivo Opportunity, LLC +310% ownerPurchase3,118$1.69$5.3KForm 4
May 20, 2026Vivo Opportunity, LLC +310% ownerPurchase51,056$1.56$79.6KForm 4
May 20, 2026Vivo Opportunity, LLC +310% ownerPurchase5,154$1.56$8KForm 4
May 19, 2026Daniel Schneeberger +110% ownerPurchase68,551$1.60$110KForm 4
May 19, 2026Daniel Schneeberger +110% ownerPurchase200,000$1.56$312KForm 4
May 19, 2026Daniel Schneeberger +110% ownerPurchase200,000$1.50$300KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Daniel Schneeberger10% owner$840K–Sep 16, 2026
Vivo Opportunity, LLC10% owner$402K–Jul 2, 2026
ADAR1 Capital Management, LLC10% owner$122K–Nov 5, 2026
Vivo Opportunity Cayman Fund, L.P.10% owner$31.8K–Jul 16, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

InMed Pharmaceuticals company events

InMed Pharmaceuticals filed 22 reports on Form 8-K in the last 12 months, 5 of them about an important change (control, listing, job cuts). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ControlChanges in Control of the Registrant. Filing
  2. Nov 9, 2026AnnouncementShared information with investors. Filing
  3. Nov 5, 2026AnnouncementShared information with investors. Filing
  4. Nov 5, 2026AnnouncementThe Company issued a press release announcing the results of its Shareholders Meeting, the Name Change and the completion of the Consolidation. Filing
  5. Nov 3, 2026AnnouncementShared information with investors. Filing
  6. Sep 18, 2026ListingInMed Pharmaceuticals Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying it that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2.5 million in… Filing
  7. Jul 22, 2026AnnouncementOf this Current Report on Form 8-K). Filing
  8. Jul 10, 2026AgreementInMed Pharmaceuticals Inc., a company incorporated under the laws of the Province of British Columbia, Indigo Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of the Company, Indigo Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the… Filing
  9. Jun 10, 2026AnnouncementAs previously reported, InMed Pharmaceuticals Inc. received a written notice on March 27, 2026 from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying it that the closing bid price of the Company's common shares over a period of 30 consecutive trading days was below the… Filing
  10. May 19, 2026ControlTo the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Filing
  11. May 19, 2026AgreementAs previously reported, pursuant to the terms of certain preferred investment options dated October 26, 2023, InMed Pharmaceuticals Inc. provided Armistice Capital Master Fund Ltd. with the right to subscribe for and purchase from the Company up to 278,761 common shares in the capital of the… Filing
  12. May 7, 2026AnnouncementShared information with investors. Filing
  13. Apr 27, 2026AgreementPreferred Investment Option Amending Agreement with Sabby Volatility Warrant Master Fund, Ltd. As previously reported, pursuant to the terms of the Preferred Investment Options dated October 26, 2023 and June 26, 2025 (together, the “Sabby Preferred Investment Options” and each a “Sabby Preferred… Filing
  14. Apr 3, 2026AnnouncementAs previously reported, InMed Pharmaceuticals Inc. entered into an At The Market Offering Agreement dated April 7, 2022, as amended by that certain amendment dated June 27, 2024, with H.C. Wainwright & Co., LLC. On April 3, 2026, the Company filed a prospectus supplement and related prospectus… Filing
  15. Mar 30, 2026ListingInMed Pharmaceuticals Inc. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying it that the closing bid price of the Company's common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for… Filing
  16. Mar 23, 2026AnnouncementShared information with investors. Filing
  17. Mar 9, 2026AnnouncementShared information with investors. Filing
  18. Mar 6, 2026Job cutsAnnounced job cuts or other exit costs. Filing
  19. Feb 12, 2026AnnouncementShared information with investors. Filing
  20. Dec 18, 2025VoteReported shareholder vote results. Filing
  21. Dec 15, 2025AnnouncementThe Company issued a news release related to the potential impact of H.R. 5371, the “Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026” that was recently signed into law in the United States on BayMedica Inc., a… Filing
  22. Nov 19, 2025AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

InMed Pharmaceuticals financials

Famous investors that hold MTRI

1 of the 50 well-known investors we track reported holding MTRI in their latest 13F filing. The largest position is Ken Griffin's, worth $58.4K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202642,972$58.4K0.0%+65%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 10 filings named MTRI in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Squadron Master Fund LP13G/A0.0%
Nov 16, 2026Squadron Master Fund LP13G/A0.0%
Nov 13, 2026Commodore Capital LP13G5.6%
Nov 13, 2026Deep Track Capital, LP13G5.6%
Nov 13, 2026Deep Track Capital, LP13G5.6%
Nov 13, 2026Commodore Capital LP13G5.6%
Nov 12, 2026Fairmount Funds Management LLC13D20.0%
Nov 12, 2026Fairmount Funds Management LLC13D20.0%
Oct 7, 2026ADAR1 Capital Management, LLC13G/A17.2%
Oct 7, 2026ADAR1 Capital Management, LLC13G/A17.2%

Questions about InMed Pharmaceuticals Inc. (MTRI) stock

Are MTRI insiders buying or selling?

In the last 12 months, MTRI insiders reported 50 open-market purchases worth $1.4M and no sales. The latest trade was on Nov 5, 2026. See every trade.

Which famous investors hold MTRI?

1 of the 50 well-known investors we track reported MTRI in their latest 13F filing, including Ken Griffin. The largest position is worth $58.4K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.